This study was undertaken to analyze the differentiation profiles assessed by immunophenotyping in AIDS-related B-cell lymphoma (ARL) and their relation to the clinical course. Paraffin-embedded sections of 89 ARL cases during 1989 to 2004 were stained immunohistochemically with antibodies to CD3, CD10, CD20, CD38, CD138/Syndecan-1 (Syn-1), multiple myeloma-1/interferon regulatory factor-4 (MUM1/IRF4), B-cell lymphoma protein-2 (BCL-2), BCL-6, latent membrane protein-1 (LMP-1), and Ki-67. Expression of CD10 and CD20 were associated with better overall survival (OS; P = .009 and P = .04, respectively). Expression of CD20 was associated with longer disease-free survival (DFS; P = .03), whereas expression of CD138/Syn-1 was associated with shorter DFS (P = .03). OS and DFS were worse in patients with immunophenotypic profiles related to post-germinal center (GC) differentiation (BCL-6 and CD10 negative, MUM1/IRF4 and/or CD138/Syn-1 positive) when compared with GC differentiation (P = .01). When controlled for age-adjusted International Prognostic Index (IPI), prior AIDS-defining illness (ADI), and year of ARL diagnosis, a post-GC differentiation remained significantly associated with poor OS and DFS. Expression of CD10 was associated with a preserved immunocompetence, whereas CD20 was less frequent in patients developing ARL while on highly active antiretroviral therapy (P = .04). In summary, lack of CD20 or CD10 expression and a post-germinal center signature are associated with a worse prognosis in ARL. (Blood. 2005;106:1762-1769)

In patients infected with HIV-1, AIDS-related lymphoma (ARL) remains one of the most frequent AIDS-defining illnesses (ADIs). Epidemiologic data suggest that since the introduction of highly active antiretroviral therapy (HAART), the decrease of the incidence of ARL has been less profound than that seen with other ADIs.1-3  ARL shares some distinctive features when compared with non-Hodgkin lymphoma (NHL) in the general population. This includes not only an almost exclusive B-cell derivation, a propensity toward advanced and extranodal disease, but also clinical aggressiveness.4,5  Despite these particular characteristics, ARL is a biologically heterogeneous disease. The different subtypes of ARL vary substantially with regard to several factors: Epstein-Barr virus and other viral infections, the extent of immune deficiency, oncogenic mutations, cytokine dysregulation, and histogenetic derivation.6-8  However, to date several studies failed to demonstrate an association between distinct histologic subtypes of ARL and prognosis.9-15 

For HIV-negative NHL, gene expression profiling using complementary DNA (cDNA) microarrays revealed that current taxonomy of lymphoma includes very heterogenous diseases. For example, distinct forms of diffuse large B-cell lymphoma (DLBCL) exist with gene expression patterns indicative of different stages of B-cell differentiation and activation.16,17  The molecular differences in the cDNA microarray technique are accompanied by a remarkable divergence in clinical behavior, reflected in a much-improved prognosis for patients with a germinal center B-like type.16  Immunohistochemical analysis on paraffin-embedded tissues is more readily available and less cost intensive than cDNA microarray and provides similar prognostic information.18  Indeed, expression of immunohistochemical markers for germinal center differentiation such as B-cell lymphoma protein-6 (BCL-6) or CD10 has been found to be predictive for favorable outcome or particular clinicopathologic features in many studies on DLBCL18-24  and also in specific entities such as cutaneous DLBCL or mucosa-associated lymphoid tissue (MALT) lymphoma.25,26  In contrast, the expression of markers indicating activation of peripheral blood B cells such as multiple myeloma-1/interferon regulatory factor-4 (MUM1/IRF4) or proto-oncogenes such as BCL-2 has been shown to have an independent adverse effect in HIV-negative NHL.18,21,23,27-30 

In ARL, data on immunohistochemical expression profiles suggest distinct categories that cluster between histogenetic subtypes.31,32  The clinical value of the histogenetic derivation patterns, however, has yet to be elucidated. In addition, data on changes in expression profiles over time are lacking. In this study, we investigated the immunohistochemical expression throughout the pathologic spectrum of AIDS-related B-cell lymphomas using a broad panel of expression and proliferation markers. Expression profiles were correlated with both clinical data and clinical course and were analyzed for changes over time.

Patients

This cohort consisted of 89 patients infected with HIV-1 with systemic high-grade ARL, diagnosed histologically between 1989 and 2004 in 3 pathology centers (St Georg Hospital, Hamburg, 36 cases; University of Kiel, 30 cases; University of Cologne, 23 cases). Baseline characteristics and ARL features are shown in Table 1. Cases had been identified by the computed database of the corresponding HIV centers located at the same institution and were selected based on the availability of paraffin-embedded tissue suitable for immunohistochemistry. Approval was obtained from the University of Kiel Institutional Review Board for these studies. Informed consent was provided according to the Declaration of Helsinki. In all patients data were evaluated with regard to demographic characteristics, HIV- and HAART-related data, ARL staging according to Ann Arbor classification,33  treatment, and remission stage of ARL according to standardized guidelines.34  As only 3 of 89 patients were older than 60, the age-adjusted International Prognostic Index (IPI)35  was calculated based on tumor stage, lactate dehydrogenase (LDH) level, and performance status. Since one or more prognostic factors were lacking in some patients, only 2 IPI groups were created for further analysis: a low-risk group (IPI 0 or 1, low and low-intermediate risk) and a high-risk group (IPI 2 or 3, high-intermediate and high risk). Chemotherapy regimens consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), comparable or more intensive regimens were considered to be curative. HAART was defined as a combination of at least 3 antiretroviral drugs. At the last follow-up on June 30, 2004, 57 of 89 patients had died, 7 were lost to follow-up, and 25 were alive. Of the 57 patients who were dead, ARL was considered to be the main cause of death in 31 cases. Fourteen patients died of ADIs. In 4 patients, it was not possible to clearly distinguish between ARL and other ADIs as leading cause of death. Five patients died of unknown reasons but without evidence of ARL recurrence. One patient died of a secondary neoplasia (CD30+ anaplastic T-cell lymphoma that occurred more than 5 years after the initial diagnosis of Burkitt lymphoma), 1 patient died of esophageal carcinoma, and 1 patient committed suicide.

Table 1.

Baseline characteristics at the time of ARL diagnosis


Characteristics

Data
No. patients studied   89  
No. men/no. women   82/7  
Age, y, mean ± SD (range)   40.9 ± 9.9 (23.0-69.1)  
Localization of ARL, no. (%)  
At least 1 extranodal manifestation   63 (71)  
Strictly nodal manifestation   26 (29)  
Ann Arbor stage, no. (%)  
I-II   25 (28)  
III-IV   61 (69)  
No staging available   3 (3)  
B symptoms   53 (63)  
Modified age adjusted IPI score, no. (%)  
Low IPI of 0 or 1   28 (31)  
High IPI of 2 or 3   51 (57)  
No IPI available   10 (11)  
Immunologic, virologic, and other parameters  
Prior AIDS diagnosis, no. (%)   27 (31)  
Absolute CD4 cell counts, cells/μL, mean ± SD (range)   201 ± 198 (0-960)  
Viral load, log copies/mL, mean ± SD (range)   4.57 ± 1.45 (0.90-6.43)  
Elevated LDH, no. (%)   53 (65)  
Hemoglobin level, g/dL, mean ± SD (range)
 
12.2 ± 2.2 (7.2-17.3)
 

Characteristics

Data
No. patients studied   89  
No. men/no. women   82/7  
Age, y, mean ± SD (range)   40.9 ± 9.9 (23.0-69.1)  
Localization of ARL, no. (%)  
At least 1 extranodal manifestation   63 (71)  
Strictly nodal manifestation   26 (29)  
Ann Arbor stage, no. (%)  
I-II   25 (28)  
III-IV   61 (69)  
No staging available   3 (3)  
B symptoms   53 (63)  
Modified age adjusted IPI score, no. (%)  
Low IPI of 0 or 1   28 (31)  
High IPI of 2 or 3   51 (57)  
No IPI available   10 (11)  
Immunologic, virologic, and other parameters  
Prior AIDS diagnosis, no. (%)   27 (31)  
Absolute CD4 cell counts, cells/μL, mean ± SD (range)   201 ± 198 (0-960)  
Viral load, log copies/mL, mean ± SD (range)   4.57 ± 1.45 (0.90-6.43)  
Elevated LDH, no. (%)   53 (65)  
Hemoglobin level, g/dL, mean ± SD (range)
 
12.2 ± 2.2 (7.2-17.3)
 

ARL indicates AIDS-related lymphoma; IPI, International Prognostic Score; LDH, lactate dehydrogenase.

Baseline characteristics. The median age of the patients was 39.8 years. The cohort included 85 whites and 4 African Americans living in Germany. The most frequent mode of HIV-1 infection was male-to-male sexual transmission (71%). Few patients reported heterosexual transmission (6%) or intravenous drug use (6%), came from pattern II countries (3%), or were hemophiliac (2%). In 12%, the mode of infection was unknown, or data were unavailable. The median time from the first positive HIV test to ARL diagnosis was 4.2 years. Profound immunosuppression at ARL diagnosis was a common finding, with only 39% having a CD4 cell count above 200 cells/μL (median CD4 cell count of 150/μL). Of 43 patients with an evaluable plasma viremia at ARL diagnosis, only 7 (16%) had a viral load of fewer than 500 copies/mL. Extranodal manifestation was a common feature as was advanced stage and an elevated LDH.

Chemotherapy. Following ARL diagnosis, 15 patients (17%) received no treatment (n = 13) or only palliative chemotherapy (n = 2). A curative chemotherapy was initiated in 74 (83%) of 89 patients which consisted of CHOP-based regimens in 66 of 74 patients (in 8 patients CHOP was intensified with etoposide). Eight patients received a more-intensive regimen that was adapted from the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL)36  and was intensified by rituximab in one patient. This was the only patient who received an additional therapy with monoclonal antibodies. A complete remission (CR) was achieved in 70% of patients starting curative chemotherapy.

Antiretroviral therapy. Before the diagnosis of ARL, 48 of the patients (54%) were naive to antiretroviral therapy (ART) and 25 (28%) had had mono- or dual-ART. Fifteen patients (17%) had received HAART for a median of 1.44 years (range, 0.31-6.73 years, 5 patients had been treated for less than 1 year), among them 80% (12 of 15) a protease inhibitor-based HAART. In one patient data on ART history was insufficient. During the first 2 years after diagnosis of ARL, 32 patients (36%) received no ART, 14 patients (16%) were treated with mono- or dual-ART, and 38 patients (43%) were on HAART. Five patients (6%) had insufficient data or follow-up was insufficient. Of the 32 patients on HAART after diagnosis of ARL during 1997 to 2004, almost all (89%) achieved at least one viral load below 500 copies/mL during follow-up.

Histology

All histologic slides were reviewed by 2 experienced hematopathologists (D.J. and M.T.). The diagnosis of ARL was based on the criteria according to the World Health Organization (WHO) classification.37  For each case, hematoxylin-eosin- and Giemsa-stained slides were studied. ARL were all of B-cell origin, indicated by a positive staining for CD20 or CD79a or heavy chain immunoglobulin rearrangement according to standard procedures.38 

Within the WHO classification, 58 (65%) of 89 cases were classified as DLBCL, including 6 cases of immunoblastic lymphoma and 11 cases that displayed morphologic features of immunoblastic large-cell lymphomas and that were later diagnosed immunohistochemically as plasmablastic lymphoma by expression of CD38 and negativity for CD20. Beside the DLBCL, 27 (30%) of 89 cases were classified as Burkitt- or Burkitt-like lymphoma (BL/BLL). Of the remaining 4 cases (5%), 1 case was classified as an undifferentiated plasmocytoma. Three cases could not be classified definitely. However, all 3 displayed, albeit unassociated with body cavity effusions, morphologic and immunohistochemical features of primary effusion lymphomas (PELs).37  These cases were probably referable to extracavitary PEL, which has been shown to apparently represent part of the spectrum of PEL.39,40  At least 2 of these cases were associated with HHV-8 infection and/or Kaposi sarcoma, and 2 lymphomas were located within the gastrointestinal tract.

Immunohistochemistry

Immunostainings were performed on 5-μm-thick serial sections from paraffin blocks from formalin-fixed biopsy specimens. Slides from each block were immunostained with antibodies to CD3, CD10, CD20 (if negative, also for CD79a), CD38, CD138/Syndecan-1 (Syn-1), BCL-6, MUM1/IRF4, BCL-2, LMP-1 (latent membrane protein-1), and Ki-67. Table 2 details the antibodies and the immunohistochemical conditions used. Antigen retrieval was achieved by boiling the sections immersed in 0.01 M citric acid, pH 6.0, for 2 minutes 30 seconds in a pressure cooker.42  The immunoreactions were enhanced either by means of the avidin-biotin complex technique43  or the alkaline phosphatase-anti-alkaline phosphatase (APAAP) method44  followed by brief counterstaining with Mayer hematoxylin.

Table 2.

Antibodies used for immunohistochemical analysis


Antibody

Source

Antigen retrieval (pH)

Dilution
CD3   Novocastra, Newcastle, United Kingdom   Citrate acid, 0.01 M, (6.0)   1:20  
CD10   Novocastra, Newcastle, United Kingdom   Citrate acid, 0.01 M, (6.0)   1:10  
CD20   Dako, Hamburg, Germany   Citrate acid, 0.01 M, (6.0)   1:5  
CD38   Novocastra, Newcastle, United Kingdom   Citrate acid, 0.01 M, (6.0)   1:100  
CD79   Dako, Hamburg, Germany   Citrate acid, 0.01 M, (6.0)   1:200  
MUM1/IRF4   Dako, Hamburg, Germany   Citrate acid, 0.01 M, (6.0)   1:50  
CD138/Syn-1   Dako, Hamburg, Germany   Citrate acid, 0.01 M, (6.0)   1:20  
BCL-2   Zytomed, Berlin, Germany   Citrate acid, 0.01 M, (6.0)   1:50  
LMP-1   Dako, Hamburg, Germany   TE buffer, (9.0)   1:200  
BCL-6   Dako, Hamburg, Germany   Target Retrieval Solution, (9.9)   1:10  
Ki-67
 
Hematopathology, Kiel, Germany41 
 
Citrate acid, 0.01 M, (6.0)
 
1:10
 

Antibody

Source

Antigen retrieval (pH)

Dilution
CD3   Novocastra, Newcastle, United Kingdom   Citrate acid, 0.01 M, (6.0)   1:20  
CD10   Novocastra, Newcastle, United Kingdom   Citrate acid, 0.01 M, (6.0)   1:10  
CD20   Dako, Hamburg, Germany   Citrate acid, 0.01 M, (6.0)   1:5  
CD38   Novocastra, Newcastle, United Kingdom   Citrate acid, 0.01 M, (6.0)   1:100  
CD79   Dako, Hamburg, Germany   Citrate acid, 0.01 M, (6.0)   1:200  
MUM1/IRF4   Dako, Hamburg, Germany   Citrate acid, 0.01 M, (6.0)   1:50  
CD138/Syn-1   Dako, Hamburg, Germany   Citrate acid, 0.01 M, (6.0)   1:20  
BCL-2   Zytomed, Berlin, Germany   Citrate acid, 0.01 M, (6.0)   1:50  
LMP-1   Dako, Hamburg, Germany   TE buffer, (9.0)   1:200  
BCL-6   Dako, Hamburg, Germany   Target Retrieval Solution, (9.9)   1:10  
Ki-67
 
Hematopathology, Kiel, Germany41 
 
Citrate acid, 0.01 M, (6.0)
 
1:10
 

Tonsil samples from routine files were used both as positive and negative controls (the latter being incubated with serum instead of the primary antibody). The immunohistochemical staining was considered as positive if 20% or closed sheets of tumor cells showed a positive staining. For the analysis of CD138/Syn-1 and MUM1/IRF4, a cut off of 50% was considered to be positive. For Ki-67 analysis, in each case nuclei from 500 neoplastic cells from randomly selected fields were counted, and the Ki-67 index was calculated as the percentage of positive cells. All cases were reviewed by 2 pathologists (M.T. and D.J.) without knowledge of the clinical data.

Statistics

Fisher exact text was used for comparison of frequencies. The Mann-Whitney U test was used for unpaired comparison of continuous variables. A P value less than .05 was considered to be statistically significant. Kaplan-Meier survival statistics were used to evaluate overall survival (OS) and disease-free survival (DFS). Overall survival was defined as the period from ARL diagnosis to death from any cause or the last contact (which was censored). To reduce the possible bias through confounding by indication resulting from association between patient's pretreatment condition and physician's treatment decision, only patients starting chemotherapy in a curative attempt were included in the univariate and multivariate analysis of OS. DFS was defined as survival without evidence of disease in patients achieving CR. Relapses or deaths from any cause were considered as events. The Cox proportional hazards model was used to evaluate the prognostic value of single immunohistochemical expression markers (CD10, CD20, CD38, CD138/Syn-1, BCL-6, MUM1/IRF4, BCL-2) and/or expression profiles (according to Chang et al20 ) on OS and DFS. Besides these expression markers or profiles, other covariables such as sex, CD4 cell counts (< 100 CD4 cells/μL), a prior AIDS event, a low IPI, and the presence of EBV infection, indicated by the presence of LMP-1, were considered as potential predictors. We also considered the time of ARL diagnosis (early = 1989-1996 versus recent = 1997-2004) as a potential predictor as this reflected best the availability and use of HAART in the patients. Entry criteria for the multivariable Cox regression analysis was a P value less than .1 in univariate analysis. Prognostic factors were identified using forward selection. All analyses were performed with the statistical program StatView (Version 5.01; SAS Institute, Cary, NC).

Clinical characteristics and outcome

In the univariate analysis, several clinical characteristics were associated with an improved OS. An improved OS was observed in patients without a previous ADI versus patients with a previous ADI (P = .01), in patients with a normal LDH level versus an elevated LDH level (P = .02), and in patients with Ann Arbor stage I/II versus stage III/IV (P = .035). LDH and tumor stage were included in the age-adjusted IPI. A low IPI score was significantly associated with an improved OS when compared with a high IPI score (P = .001). No bone marrow involvement (P = .025) and no more than one extranodal manifestation (P = .01) were also associated with increased OS. No differences were observed regarding sex or histology (DLBCL versus BL/BLL versus others). Neither was CD4 cell count at ARL diagnosis predictive, although there was a trend toward a poorer OS in patients with an absolute number of fewer than 100 CD4 cells/μL (P = .09). When analyzing differences between the time intervals 1989 to 1996 and 1997 to 2004, OS was significantly improved within the later period (P = .025). With regard to DFS, a low IPI (P = .01) and no more than one extranodal manifestation (P = .001) were significantly associated with a better outcome. DFS showed no significant difference between the 2 time intervals.

Immunohistochemical expression markers and clinical characteristics

The results of the immunohistochemical analysis and the frequencies of the expression of single markers are shown in Table 3. Representative examples of positive or negative immunohistochemical staining of single markers are depicted in Figure 1A-H. As shown in Table 3, marked differences exist between the different histologic subtypes. For example, whereas the vast majority of DLCBL (immunoblastic and plasmablastic lymphoma excluded) and of BL/BLL showed a CD20 expression, in the remaining cases CD20 expression was rarely seen. Of the 22 cases that stained negative for CD20, 86% (19 of 22) expressed CD38, 85% (17 of 20) expressed MUM1/IRF4, and 52% (11 of 21) expressed CD138/Syn-1. In contrast, only 24% (5 of 21) of cases which stained negative for CD20 expressed CD10, 14% (3 of 22) expressed BCL-2, and 14% (3 of 22) expressed BCL-6. In contrast to markers such as CD10, CD20, and BCL-6, the expression of markers indicating a post-germinal center signature such as CD138/Syn-1 or MUM1/IRF4 was a rare event in DLBCL and BL/BLL cases. In contrast, a high number of the remaining cases stained positive for CD138/Syn-1 or MUM1/IRF4.

Table 3.

Expression frequency of single markers within the cohort and histopathologic subgroups




All, % (no./no. total)

DLBCL, % (no./no. total)*

BL/BLL, % (no./no. total)

Others, % (no./no. total)

P
CD3   0 (0/89)   0 (0/41)   0 (0/27)   0 (0/21)   —  
CD10   49 (43/88)   41 (17/41)   81 (22/27)   20 (4/20)   < .001  
CD20   75 (67/89)   98 (40/41)   89 (24/27)   14 (3/21)   < .001  
BCL-6   65 (57/88)   83 (34/41)   78 (21/27)   10 (2/20)   < .001  
CD38   48 (42/88)   29 (12/41)   52 (14/27)   80 (16/20)   < .001  
MUM1/IRF4   45 (34/75)   29 (10/35)   36 (8/22)   89 (16/18)   < .001  
CD138/Syn-1   15 (12/80)   3 (1/36)   4 (1/26)   56 (10/18)   < .001  
LMP-1   20 (17/83)   20 (8/41)   12 (3/26)   38 (6/16)   .126  
BCL-2
 
20 (18/89)
 
29 (12/41)
 
15 (4/27)
 
14 (2/21)
 
.131
 



All, % (no./no. total)

DLBCL, % (no./no. total)*

BL/BLL, % (no./no. total)

Others, % (no./no. total)

P
CD3   0 (0/89)   0 (0/41)   0 (0/27)   0 (0/21)   —  
CD10   49 (43/88)   41 (17/41)   81 (22/27)   20 (4/20)   < .001  
CD20   75 (67/89)   98 (40/41)   89 (24/27)   14 (3/21)   < .001  
BCL-6   65 (57/88)   83 (34/41)   78 (21/27)   10 (2/20)   < .001  
CD38   48 (42/88)   29 (12/41)   52 (14/27)   80 (16/20)   < .001  
MUM1/IRF4   45 (34/75)   29 (10/35)   36 (8/22)   89 (16/18)   < .001  
CD138/Syn-1   15 (12/80)   3 (1/36)   4 (1/26)   56 (10/18)   < .001  
LMP-1   20 (17/83)   20 (8/41)   12 (3/26)   38 (6/16)   .126  
BCL-2
 
20 (18/89)
 
29 (12/41)
 
15 (4/27)
 
14 (2/21)
 
.131
 

Total number tested was 89; for DLBCL, n = 41; for BL/BLL, n = 27; and for others, n = 21.

DLBCL indicates diffuse large B-cell lymphoma; BL/BLL, Burkitt and Burkitt-like lymphoma; and —, not applicable.

*

From the DLBCL, immunoblastic and plasmablastic lymphoma were excluded.

This group included in 6 immunoblastic, 11 plasmablastic lymphoma, 1 undifferentiated plasmocytoma, and 3 cases that displayed morphologic features of primary effusion lymphomas.

Chi-square test, comparing frequencies of markers in the 3 histopathologic subgroups.

We also found some associations between single expression markers and clinical characteristics. Expression of CD10 was significantly associated with a relatively preserved immunocompetence at ARL diagnosis, reflected by a higher proportion of patients with CD4 counts more than 100/μL (P = .008) and with no previous ADI (P = .006). Expression of CD20 was associated with an elevated LDH at ARL diagnosis (P = .03). No other significant associations between expression profile and clinical data were found.

The median percentage of Ki-67-expressing cells was 84%, with a slightly higher percentage in cases that expressed CD10 compared with cases without CD10 expression (89% versus 80%, P = .09). A trend toward a higher percentage was also seen in cases expressing CD20 when compared with cases without CD20 expression (86% versus 80%, P = .11). No other trends were observed between the frequency of Ki-67-expressing cells and other markers.

Expression profiles did not change over time when the time periods between 1989 to 1996 and 1997 to 2004 were compared. No trend could be demonstrated, irrespective whether other/smaller time intervals were chosen. However, analysis of the subgroup of patients developing ARL despite the use of HAART (n = 15; median time on HAART at ARL diagnosis, 1.44 years; 12 of 15 of the patients received a protease inhibitor-based regimen) revealed a high proportion (7 of 15, 47%) of ARL cases without CD20 expression. In contrast, ARL without CD20 expression occurred in only 19% (14 of 73) of patients who were not treated with HAART. This difference was statistically significant (P = .04). Even in the subgroup of patients who developed ARL while having a controlled HIV infection on HAART (HIV plasma viremia of less then 500 copies/mL, n = 7), remained a trend toward cases without CD20 expression (P = .06).

Figure 1.

Immunohistochemical staining, APAAP method. (A) DLBCL, centroblastic subtype, CD20 staining with positive tumor cells, × 40; (B) Burkitt-like lymphoma, CD20 staining with negative tumor cells and positive reactive lymphocytes, × 40; (C) DLBCL, centroblastic subtype, CD10 staining with positive tumor cells, × 40; (D) plasmablastic lymphoma, CD10 staining with negative tumor cells, × 40; (E) DLBCL, immunoblastic subtype, CD138 staining with positive tumor cells, × 40; (F) DLBCL, CD138 staining with negative tumor cells and positive reactive plasma cells, × 40; (G) Burkitt lymphoma, MUM1 staining with positive tumor cells, × 40; (H) DLBCL, centroblastic subtype, MUM1 staining with negative tumor cells and positive reactive plasma cells, × 40. Images were visualized in Zeiss Immersol S18N under an Axioskop 2 Plus microscope (Zeiss, Oberkochen, Germany) equipped with a Plan Apochromat 40 ×/1.0 oil objective lens; the iris aperture was 1.0. A Sony 3 CCD color video camera MC3289 (Sony, Tokyo, Japan) and DSH Bilddatenbank software (Greifenstein, Germany) were used for image acquisition.

Figure 1.

Immunohistochemical staining, APAAP method. (A) DLBCL, centroblastic subtype, CD20 staining with positive tumor cells, × 40; (B) Burkitt-like lymphoma, CD20 staining with negative tumor cells and positive reactive lymphocytes, × 40; (C) DLBCL, centroblastic subtype, CD10 staining with positive tumor cells, × 40; (D) plasmablastic lymphoma, CD10 staining with negative tumor cells, × 40; (E) DLBCL, immunoblastic subtype, CD138 staining with positive tumor cells, × 40; (F) DLBCL, CD138 staining with negative tumor cells and positive reactive plasma cells, × 40; (G) Burkitt lymphoma, MUM1 staining with positive tumor cells, × 40; (H) DLBCL, centroblastic subtype, MUM1 staining with negative tumor cells and positive reactive plasma cells, × 40. Images were visualized in Zeiss Immersol S18N under an Axioskop 2 Plus microscope (Zeiss, Oberkochen, Germany) equipped with a Plan Apochromat 40 ×/1.0 oil objective lens; the iris aperture was 1.0. A Sony 3 CCD color video camera MC3289 (Sony, Tokyo, Japan) and DSH Bilddatenbank software (Greifenstein, Germany) were used for image acquisition.

Close modal

Immunohistochemical expression markers and outcome

Testing expression markers for their predictive value for OS, a significant benefit for CD10 expression was found in the univariate analysis. The estimated median OS in cases with CD10 expression was 5.3 versus 0.9 years in cases without CD10 expression (P = .009). The difference remained significant when only DLBCL cases were analyzed, even after the exclusion of immunoblastic and plasmablastic subtypes (P = .01). A significantly improved OS was also observed for CD20 expression. The estimated median OS in cases with CD20 expression was 2.9 years versus 0.9 years in cases without CD20 expression (P = .04). Kaplan-Meier curves for OS for both markers, CD10 and CD20, are depicted in Figure 2A-B.20  Although a trend was seen toward an improved OS in patients with ARL staining positive for BCL-6 or with negative staining for CD38, MUM1/IRF4 (Figure 2C) or CD138/Syn-1, these differences did not reach statistical significance.

Figure 2.

Kaplan-Meier curves (univariate analysis). Kaplan-Meier curves (univariate analysis) for cases with or without CD10 expression (A), CD20 expression (B), MUM1/IRF4 expression (C), BCL-2 expression (D), and for the 3 patterns according to Chang et al20  (E). In this model, pattern A indicates a GC B-cell pattern (expression of GC B-cell markers such as CD10 and/or BCL-6 but not of activation markers such as MUM1/IRF4 or CD138/Syn-1). Pattern B indicates an activated GC B-cell pattern (expression of at least one GC B-cell marker and of one activation marker). Pattern C indicates an activated non-GC B-cell pattern (expression of MUM1/IRF4 and/or CD138/Syn-1 but not of GC B-cell markers). For all Kaplan-Meier statistics, only patients with a curative chemotherapy were analyzed (n = 74).

Figure 2.

Kaplan-Meier curves (univariate analysis). Kaplan-Meier curves (univariate analysis) for cases with or without CD10 expression (A), CD20 expression (B), MUM1/IRF4 expression (C), BCL-2 expression (D), and for the 3 patterns according to Chang et al20  (E). In this model, pattern A indicates a GC B-cell pattern (expression of GC B-cell markers such as CD10 and/or BCL-6 but not of activation markers such as MUM1/IRF4 or CD138/Syn-1). Pattern B indicates an activated GC B-cell pattern (expression of at least one GC B-cell marker and of one activation marker). Pattern C indicates an activated non-GC B-cell pattern (expression of MUM1/IRF4 and/or CD138/Syn-1 but not of GC B-cell markers). For all Kaplan-Meier statistics, only patients with a curative chemotherapy were analyzed (n = 74).

Close modal

A significantly improved DFS was seen with CD20 (P = .03) but not with CD10 expression. A trend toward a better DFS was also seen for BCL-6 expression (P = .09). In contrast, CD138/Syn-1 expression was significantly associated with poor DFS (P = .03). These results did not change significantly when patients who died because of an AIDS-defining illness without evidence of ARL recurrence were censored (data not shown). Other staining patterns showed no significant correlations with DFS. BCL-2 or LMP-1 staining pattern had neither effect on OS (for BCL-2, see Figure 2D) or DFS in the whole cohort or in any subgroups tested.

Immunohistochemical expression profiles

To analyze the immunohistochemical expression profiles, we first used the histogenetic model for ARL proposed in this journal.31,32  Using 3 markers, namely BCL-6, MUM1/IRF4, and CD138/Syn-1, this model distinguishes between 3 major phenotypic patterns (A, B, C) that display preferential associations with specific clinicopathologic categories. Pattern A reflects GC centroblasts and MUM1/IRF4-negative centrocytes (expression of BCL-6 only) and is associated with BL and DLBCL. Pattern B reflects late GC/early post-GC B cells (expression of MUM1/IRF4 only) and is associated with immunoblastic ARL. Pattern C reflects post-GC B cells (expression of both MUM1/IRF4 and CD138/Syn-1) and is strongly associated with PEL and plasmablastic lymphoma.32  When we applied this model to our cohort, OS and DFS were significantly improved in patients attributed to pattern A than in patients attributed to the other 2 patterns (P = .02 and P = .03, respectively). However, whereas we found remarkable parallels in overall staining frequencies for these expression markers as described by Carbone et al,32  and although the reported clustering of single markers within histologic subtypes was highly reproducible, only 53% (47 of 89) cases in our cohort could be applied to 1 of these 3 profiles. Because we were more interested in expressing profiles of prognostic value than of associations with specific pathologic categories, we used various models to include as many cases as possible. This was achieved most successfully with a model that has recently shown to be relevant in HIV-negative DLBCL.20  In this model proposed by Chang et al20  cases are classified into a GC B-cell pattern (pattern A*, expression of GC B-cell markers such as CD10 and/or BCL-6 but not of activation markers such as MUM1/IRF4 and CD138/Syn-1), an activated GC B-cell pattern (pattern B*, expression of at least one of GC B-cell markers and of one of the activation markers), and an activated non-GC B-cell pattern (pattern C*, expression of MUM1/IRF4 and/or CD138/Syn-1 but not of GC B-cell markers).20  With this model, 89% (79 of 89) of the patients in our cohort were classifiable.

Immunohistochemical expression profiles and outcomes

As shown in Figure 2E, patients with pattern C had a significantly poorer OS in the univariate analysis than those with the other 2 patterns (P = .01, when pattern A and B were both combined, P = .003). Of note, patterns A and B did not differ, suggesting that in ARL, the expression of MUM1/IRF4 or CD138/Syn-1 bears only an adverse effect when GC B-cell markers are completely lacking.

The remaining variables to be included in the Cox model for OS were CD10, CD20, and a post-GC differentiation according to Chang et al,20  a prior AIDS event, a CD4 cell count below 100/μL, a low age-adjusted IPI, and a more recent diagnosis of ARL. Four of these variables were identified as independent predictors for OS using forward selection, namely a post-GC differentiation, no prior AIDS event, a low age-adjusted IPI, and a more recent diagnosis of ARL (see Table 4). Including the use of HAART (the relative hazard of “HAART use” when compared with “no HAART use” was 0.17; 95% CI, 0.08-0.38; P < .001) instead of the year of diagnosis as a covariable in the multivariable model, the results did not change significantly (data not shown). The relative hazard for HAART use was slightly lower compared with the relative hazard of an ARL diagnosis in 1997 to 2004, but the difference was not statistically significant.

Table 4.

Cox models: remaining variables for overall survival and for disease-free survival




RH (95% CI)

P
Overall survival   
No prior AIDS-defining illness, versus yes   0.41 (0.18-0.94)   .036  
Diagnosis 1997-2004, versus 1989-1996   0.34 (0.16-0.69)   .003  
Post-GC differentiation, versus activated GC or GC   3.98 (1.45-10.93)   .007  
Low IPI, versus high   0.37 (0.18-0.76)   .007  
Disease-free survival   
Post-GC differentiation, versus activated GC or GC   35.20 (4.32-287.05)   .001  
Low IPI, versus high
 
0.33 (0.13-0.81)
 
.015
 



RH (95% CI)

P
Overall survival   
No prior AIDS-defining illness, versus yes   0.41 (0.18-0.94)   .036  
Diagnosis 1997-2004, versus 1989-1996   0.34 (0.16-0.69)   .003  
Post-GC differentiation, versus activated GC or GC   3.98 (1.45-10.93)   .007  
Low IPI, versus high   0.37 (0.18-0.76)   .007  
Disease-free survival   
Post-GC differentiation, versus activated GC or GC   35.20 (4.32-287.05)   .001  
Low IPI, versus high
 
0.33 (0.13-0.81)
 
.015
 

RH indicates relative hazards for death from any cause (overall survival) and for relapse or death from any cause (disease-free survival); GC, germinal center; IPI, International Prognostic Score.

Because there was a moderate-to-high correlation between CD10, CD20, and post-GC differentiation, these markers or profiles could not be identified as independent from each other, and only one marker or profile remained in the model. However, when controlling CD10 or CD20 expression each solely for age-adjusted IPI, prior AIDS and year of ARL diagnosis (early versus recent), they remained significantly associated with OS. OS was significantly improved in cases with CD10 expression (hazard ratio [HR], 0.47; 95% CI, 0.24-0.92; P = .03) and with CD20 expression (HR, 0.24; 95% CI, 0.10-0.60; P = .002).

We also performed Cox regression analysis for DFS. In this model, only a low IPI and a post-GC differentiation were identified as independent prognostic factors (see Table 4). These results did not change significantly when patients who died of AIDS without evidence of recurrence were censored (data not shown).

To our knowledge, this is the first study analyzing the association between immunohistochemical expression profiles and their relation to clinical course and characteristics in a large cohort of AIDS-related lymphoma. We demonstrated that the presence of a signature indicating a post-germinal center (GC) stage is associated with a worse OS and DFS when compared with ARL with an activated GC or GC signature. Beside a prior AIDS diagnosis, an early ARL diagnosis (in the pre-HAART era) and a high IPI, a post-GC signature was independently predictive for a worse OS and a worse DFS. When the use of HAART (which was also significantly associated with a better prognosis) was included in the model instead of the year of diagnosis, results did not change significantly.

Thus, our findings implicate the clinical relevance of the histogenetic model for ARL that was proposed by Carbone et al31,32  in this journal. This model segregates 3 major phenotypic patterns, reflected by the expression of the 3 markers BCL-6, MUM1/IRF4, and CD138/Syn-1, which correspond to distinct stages of physiologic B-cell development. However, we propose the addition of CD10 to these profiles. CD10 is a cell-surface metalloproteinase that has a restricted expression in the germinal center cells and that has been shown to be a reliable marker of follicular center B-cell differentiation.45 

Applying our expression results to a model that includes CD10 as a further marker,20  a significant larger group of cases could be classified in our cohort. In addition, we showed that in ARL the presence of activation markers such as MUM1/IRF4 and CD138/Syn-1 bears only an adverse effect when GC markers such as BCL-6 or CD10 are completely lacking. The differences between phenotypic patterns regarding outcome remained also significant when only patients with low or high IPI were analyzed (data not shown).

This study also showed CD10 expression (alone and as part of the GC expression profile) to be predictive for an improved OS. This was seen in the whole cohort but was also seen in the subgroup of DLBCL. It should be mentioned that CD10 expression was not predictive with regard to DFS and that CD10 was significantly associated with a preserved immunocompetence at the time of ARL diagnosis. However, CD10 expression has been shown to be predictive for OS in several studies of different cohorts of HIV-negative NHL.18-20,24,26  CD10 expression is also associated with increased apoptosis and proliferation in HIV-negative DLBCL.46  Our analysis of expression of Ki-67 protein with monoclonal antibodies41  revealed a trend toward a higher proliferation in cases expressing CD10. Given that the classification of lymphoma in patients infected with HIV is difficult even for experienced pathologists and that most studies on ARL found no association between distinct histologic features and outcome,9-15  we recommend that CD10 be included in the histopathologic routine panel of ARL diagnosis.

In addition to CD10 expression, CD20 expression also was of prognostic value concerning OS and DFS in our study. Of note, the cohort had a relatively high frequency of CD20- cases (25%), reflecting not only a relatively large subgroup of plasmablastic lymphoma but also some lymphomas that resembled morphologically and immunohistochemically primary effusion lymphoma. These entities typically lack CD20 expression, and some small studies have reported on a poor outcome of patients with these lymphomas.41,47-49  CD20 expression was associated with a higher frequency of an elevated LDH, indicating that these ARL have a higher proliferation rate. Indeed, CD20 expression was associated with a higher percentage of cells that stained positive for the proliferation marker Ki-67.

Our findings may have important implications regarding therapeutic strategies. Given the enhanced tolerability of chemotherapy in patients infected with HIV in the HAART era50-52  and given the poor outcome in patients without CD10 and/or CD20 expression or with a post-germinal profile (almost all of them were treated with CHOP-based regimens), one could consider more intensive approaches in these patients. However, our retrospective data should be confirmed by prospective studies.

As previously reported,53,54  we rarely found an expression of BCL-2 in ARL. This may be also of clinical relevance, as studies on HIV-negative DLBCL indicate that patients without BCL-2 expression may not benefit from the additional use of monoclonal antibodies such as rituximab.55,56  In the light of newer data on high rates of infectious complications in patients with ARL treated with rituximab in one large randomized trial,57  the use of this monoclonal antibody remains questionable in patients infected with HIV. In our cohort, only one patient received rituximab. Of note, BCL-2 had no effect on DFS and OS in our cohort, regardless of which subgroup was analyzed. This contrasts with many studies in the HIV-negative setting.19,21,23,25,27-29  The reason for this difference remains unclear. However, the low expression of BCL-2 in ARL suggests that this protooncogene is infrequently involved in the pathogenic mechanisms contributing to ARL.

We were also interested in the changes of the expression profiles of ARL over time, because there is conflicting data on changes in the pathologic spectrum of ARL in the era of HAART. Whereas some studies revealed no significant changes,58,59  other investigators found larger proportions of cases with an unknown histology or a histology other than DLBCL or BL.2  In contrast, some reported on an increase of DLBCL60  in the HAART era. Data on changes in expression profiles over time are lacking. However, some investigators hypothesized that the improved immune function associated with HAART may lead to a shift in pathogenesis away from lymphomas of post-germinal center B-like origin.53  Such a shift was not evident when we performed a correlational analysis determining the influence of HAART by defining different time intervals according to changes in the availability of antiretroviral therapy. However, when analyzing possible HAART effects on the individual patient data level, the expression of CD20 was rarely seen in patients who were treated with HAART before ARL occurred, although the numbers of such patients in our cohort were too low to draw definite conclusions. Moreover, the time period on HAART at ARL diagnosis was relatively short in some patients, indicating that at least in some individuals the events triggering lymphogenesis had possibly already occurred at the time of HAART initiation. Future studies should analyze possible HAART effects on the individual patient data level because many ARL occur in untreated patients. In our previous study on 203 cases, only 46% of the patients developing ARL between 1997 and 2001 had received HAART at the time of ARL diagnosis.10 

In summary, our data demonstrate the clinical relevance of immunohistochemical expression profiles that correspond to distinct stages of physiologic B-cell development. They also indicate that CD10, alone or as part of the post-GC expression profile, and CD20 expression are important predictors of clinical outcome in AIDS-related lymphoma. Given the poor outcome of patients with ARL, indicating a post-germinal center signature, these observations may, if confirmed by prospective studies, lead to distinct therapeutic strategies.

Prepublished online as Blood First Edition Paper, May 19, 2005; DOI 10.1182/blood-2004-12-4631.

C.H. and M.T. contributed equally to the study.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.
J Natl Cancer Inst.
2000
;
92
:
1823
-1830.
2
Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy.
Blood.
2001
;
98
:
3406
-3412.
3
Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study.
Lancet.
2000
;
356
:
291
-296.
4
Gaidano G, Capello D, Carbone A. The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis.
Semin Oncol.
2000
;
27
:
431
-441.
5
Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects.
Semin Oncol.
2000
;
4
:
442
-453.
6
Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma.
Hematol Oncol Clin N Am.
2003
;
17
:
785
-820.
7
Porcu P, Caligiuri MA. Acquired immunodeficiency syndrome-related lymphomas: future directions.
Semin Oncol.
2000
;
27
:
454
-462.
8
Tirelli U, Spina M, Gaidano G, Vaccher E, Franceschi S, Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy.
AIDS.
2000
;
14
:
1675
-1688.
9
Gabarre J, Raphael M, Lepage E, et al. Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes.
Am J Med.
2001
;
111
:
704
-711.
10
Hoffmann C, Wolf E, Fatkenheuer G, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma.
AIDS.
2003
;
17
:
1521
-1529.
11
Levine AM, Sullivan-Halley J, Pike MC, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival.
Cancer.
1991
;
68
:
2466
-2472.
12
Roithmann S, Toledano M, Tourani JM, et al. HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors.
Ann Oncol.
1991
;
2
:
289
-295.
13
Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142: low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases.
J Clin Oncol.
1998
;
16
:
3601
-3606.
14
Thiessard F, Morlat P, Marimoutou C, et al. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997.
Cancer.
2000
;
88
:
1696
-1702.
15
Vaccher E, Tirelli U, Spina M, et al. Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: a single-institute study of 96 patients.
J Clin Oncol.
1996
;
14
:
2217
-2223.
16
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature.
2000
;
403
:
503
-511.
17
Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
N Engl J Med.
2002
;
346
:
1937
-1947.
18
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Blood.
2004
;
103
:
275
-282.
19
Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
Blood.
2002
;
99
:
1136
-1143.
20
Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.
Am J Surg Pathol.
2004
;
28
:
464
-470.
21
Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
Blood.
2003
;
101
:
78
-84.
22
Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.
Blood.
2001
;
98
:
945
-951.
23
Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.
N Engl J Med.
2004
;
350
:
1828
-1837.
24
Ohshima K, Kawasaki C, Muta H, et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis.
Histopathology.
2001
;
39
:
156
-162.
25
Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas.
Blood.
2004
;
103
:
3662
-3668.
26
Ponzoni M, Ferreri AJ, Pruneri G, et al. Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome.
Int J Cancer.
2003
;
106
:
288
-291.
27
Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma.
Blood.
1996
;
87
:
265
-272.
28
Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.
Blood.
1996
;
88
:
1046
-1051.
29
Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.
Blood.
1997
;
90
:
244
-251.
30
Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Blood.
2002
;
99
:
2685
-2693.
31
Carbone A, Gaidano G, Gloghini A, et al. Differential expression of BCL-6, CD138/syndecan-1 and EBV-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas.
Blood.
1998
;
91
:
747
-755.
32
Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas.
Blood.
2001
;
97
:
744
-751.
33
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification.
Cancer Res.
1971
;
31
:
1860
-1861.
34
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
J Clin Oncol.
1999
;
17
:
1244
.
35
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.
N Engl J Med.
1993
;
329
:
987
-994.
36
Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia.
Blood.
1996
;
87
:
495
-508.
37
Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.
J Clin Oncol.
1999
;
17
:
3835
-3849.
38
Wan JH, Trainor KJ, Brisco MJ, Morley AA. Monoclonality in B cell lymphoma detected in paraffin wax embedded sections using the polymerase chain reaction.
J Clin Pathol.
1990
;
43
:
888
-890.
39
DePond W, Said JW, Tasaka T, et al. Kaposi's sarcoma-associated herpesvirus and human herpesvirus 8 (KSHV/HHV8)-associated lymphoma of the bowel. Report of two cases in HIV-positive men with secondary effusion lymphomas.
Am J Surg Pathol.
1997
;
21
:
719
-724.
40
Huang Q, Chang KL, Gaal K, Arber DA. Primary effusion lymphoma with subsequent development of a small bowel mass in an HIV-seropositive patient: a case report and literature review.
Am J Surg Pathol.
2002
;
26
:
1363
-1367.
41
Kreipe H, Wacker HH, Heidebrecht HJ, et al. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen.
Am J Pathol.
1993
;
142
:
1689
-1694.
42
Bankfalvi A, Riehemann K, Ofner D, et al. Moist autoclaving. A simplified method for antigen unmasking.
Pathologe.
1994
;
15
:
345
-349.
43
Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics.
Am J Clin Pathol.
1981
;
75
:
816
-821.
44
Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).
J Histochem Cytochem.
1984
;
32
:
219
-229.
45
Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas.
Am J Surg Pathol.
2000
;
24
:
846
-852.
46
Bai M, Agnantis NJ, Skyrlas A, et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas.
Mod Pathol.
2003
;
16
:
471
-480.
47
Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection.
Blood.
1997
;
89
:
1413
-1420.
48
Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.
Am J Surg Pathol.
2004
;
28
:
736
-747.
49
Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study.
J Clin Oncol.
2003
;
21
:
3948
-3954.
50
Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.
AIDS.
2001
;
15
:
1483
-1491.
51
Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
AIDS.
2002
;
16
:
531
-536.
52
Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
J Clin Oncol.
2001
;
19
:
2171
-2178.
53
Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Blood.
2003
;
101
:
4653
-4659.
54
Schlaifer D, Krajewski S, Galoin S, et al. Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection.
Am J Pathol.
1996
;
149
:
177
-185.
55
Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Blood.
2003
;
101
:
4279
-4284.
56
Wilson WH, Pittaluga S, O'Connor P, et al. Rituximab may overcome BCL-2-associated chemotherapy resistance in untreated diffuse large B-cell lymphomas [abstract].
Blood.
2001
;
98
(11 Pt 1):
1447a
.
57
Kaplan L. No benefit from Rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIV-associated Non-Hodgkin's Lymphoma: AIDS Malignancies Consortium Study 010 (abstract S17). Presented at the
7th AIDS Malignancy Conference
2003
, Bethesda, MD.
58
Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy.
Blood.
2001
;
98
:
2339
-2344.
59
Gerard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival.
J Acquir Immune Defic Syndr.
2002
;
30
:
478
-484.
60
Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma.
Blood.
2000
;
96
:
4084
-4090.
Sign in via your Institution